Greenwich LifeSciences, Inc.
GLSI
$11.67
-$0.26-2.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.02% | -64.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.27% | -59.40% | |||
| Operating Income | -23.27% | 59.40% | |||
| Income Before Tax | -23.54% | 59.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.54% | 59.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.54% | 59.47% | |||
| EBIT | -23.27% | 59.40% | |||
| EBITDA | -23.27% | 59.41% | |||
| EPS Basic | -21.67% | 59.54% | |||
| Normalized Basic EPS | -21.73% | 59.55% | |||
| EPS Diluted | -21.67% | 59.54% | |||
| Normalized Diluted EPS | -21.73% | 59.55% | |||
| Average Basic Shares Outstanding | 1.51% | 0.18% | |||
| Average Diluted Shares Outstanding | 1.51% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||